Anti-methanogenic lovastatin analogs or derivatives and uses thereof
AssigneeCedars-Sinai Medical Center
InventorsMark Pimentel, Vince Wacher
Life of this patent
Estimating the term…
Abstract
The present invention relates to, in part, methods for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS) using at least one anti-methanogenic lovastatin analog or derivative. In addition, modified-release formulations comprising at least one anti-methanogenic lovastatin analog or derivative are provided which release the anti-methanogenic lovastatin analog or derivative in the gastrointestinal tract.
Claims12
A method for treating irritable bowel syndrome (IBS) or constipation-associated IBS (IBS-C) in a human subject, comprising:
- administering to the subject a modified-release formulation comprising
- a coating having a pH-dependent erosion profile;
- and
- an effective amount of lovastatin diol lactone releasably enclosed within the coating,
- wherein the modified-release formulation releases at least 60% of the lovastatin diol lactone into the small and/or large intestine of the subject,
- wherein the modified-release formulation avoids or reduces systemic exposure to lovastatin diol lactone,
- wherein the modified-release formulation reduces or inhibits methanogenesis in the small and/or large intestine, and
- wherein the lovastatin diol lactone does not result in effective inhibition of HMG-CoA reductase in the subject.
A method for treating irritable bowel syndrome (IBS) or constipation-associated IBS (IBS-C) in a human subject, comprising:
- administering an effective amount of a lovastatin diol lactone to a human subject in need thereof,
- wherein the lovastatin diol lactone is in a modified-release formulation comprising a coating having a pH-dependent erosion profile and having the lovastatin diol lactone releasably enclosed therein for release in the gastrointestinal (GI) tract of a human,
- wherein the modified-release formulation releases at least 60% of the lovastatin diol lactone into the small and/or large intestine,
- wherein the administration of the lovastatin diol lactone in the modified-release formulation avoids or reduces systemic exposure to the lovastatin diol lactone,
- wherein the modified-release formulation reduces or inhibits methanogenesis in the small and/or large intestine, and
- wherein the lovastatin diol lactone does not result in effective inhibition of HMG-CoA reductase in the human subject.
Dependencies are inferred from the claim text.